Skin Microbiome Composition for Atopic Dermatitis Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The relationship between skin normal bacterial flora and skin diseases, particularly atopic dermatitis, is not well understood, and existing treatments do not effectively address the underlying bacterial influences on dermatitis.
Innovation Solution
A pharmaceutical composition is developed using specific bacteria from the genus Staphylococcus, particularly S. cohnii, which are resistant to ampicillin and fusidic acid, to modulate the immune response and treat dermatitis by enhancing glucocorticoid gene expression and suppressing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional antibiotics (ampicillin, fusidic acid) are used to treat skin infections, then bacterial proliferation is suppressed, but the skin normal bacterial flora is disrupted and resistance develops
Solution Approach 1:
The patent identifies that certain skin commensal bacteria (Staphylococcus epidermidis, Staphylococcus cohnii, Staphylococcus lugdunesis) that are normally present on healthy skin actually have protective effects against atopic dermatitis. These bacteria produce antimicrobial peptides and modulate immune responses, converting what were previously considered merely neutral commensals into beneficial therapeutic agents. The invention shifts the paradigm from treating skin infections by killing all bacteria to selectively utilizing beneficial commensal bacteria for treatment.
Solution Approach 2:
Instead of using antibiotics to eliminate harmful bacteria, the patent inverts the approach by introducing and cultivating beneficial commensal bacteria on the skin surface. The therapeutic strategy involves applying live or cultured commensal bacteria (such as S. epidermidis, S. cohnii, or S. lugdunesis) to the skin, allowing them to colonize and exert protective effects, thereby reversing the conventional wisdom that skin infections are treated by broad-spectrum antibiotic elimination of all bacteria.
2Ease of operation
If the skin barrier is compromised in atopic dermatitis, then penetration of substances is improved, but inflammation and itching increase
Solution Approach 1:
The patent introduces commensal bacteria as intermediary agents that mediate between the compromised skin barrier and the external environment. These bacteria colonize the skin surface, produce antimicrobial peptides, and modulate immune responses, thereby protecting against inflammation and itching while maintaining a degree of barrier integrity. The bacteria act as a protective intermediary layer that prevents direct contact between pathogens and the compromised skin.
Solution Approach 2:
The commensal bacteria utilized in the patent are capable of self-colonization and self-maintenance on the skin surface. When applied topically, the bacteria adhere to the skin, establish their own population, and autonomously produce protective substances such as antimicrobial peptides. This self-service capability allows the bacteria to maintain protective functions without requiring continuous external intervention or complex delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prevents, ameliorates, and treats dermatitis by leveraging the suppressive effects of these bacteria, enhancing glucocorticoid gene expression and reducing inflammation, thereby improving the quality of life for patients.
Implementation Method 1
these bacteria act on the host and enhance the glucocorticoid gene expression in the host
Data Source
AI summary
In the present invention, the influence by flora of the skin on dermatitis is examined by analyzing Tmem79-knockout model mice, and a bacterium having a suppressive effect on dermatitis is identified, and the present invention relates to a pharmaceutical composition derived from such a bacterium, containing as active components one or more substances selected from: (a) a bacterial cell of an ampicillin-sensitive bacterium, or a constituent component of the bacterium; (b) a culture supernatant of an ampicillin-sensitive bacterium, or a purified product from the culture supernatant; (c) an extract of an ampicillin-sensitive bacterium; and (d) a metabolite of an ampicillin-sensitive bacterium.